{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:30:43Z","timestamp":1776288643476,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00106-023-01315-9","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T16:01:27Z","timestamp":1685721687000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chemotherapieinduzierte Nausea und Emesis","Chemotherapy-induced nausea and vomiting"],"prefix":"10.1007","volume":"71","author":[{"given":"Meinolf","family":"Karthaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"issue":"16","key":"1315_CR1","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJM198110153051609","volume":"305","author":"J Laszlo","year":"1981","unstructured":"Laszlo J, Lucas VS Jr. (1981) Emesis as a\u00a0critical problem in chemotherapy. N\u00a0Engl J Med 305(16):948\u2013949","journal-title":"N Engl J Med"},{"issue":"10","key":"1315_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1200\/JCO.1985.3.10.1379","volume":"3","author":"MG Kris","year":"1985","unstructured":"Kris MG, Gralla RJ, Clark RA, Tyson LB, O\u2019Connell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J\u00a0Clin Oncol 3(10):1379\u20131384. https:\/\/doi.org\/10.1200\/JCO.1985.3.10.1379","journal-title":"J Clin Oncol"},{"issue":"4","key":"1315_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/1097-0142(19820815)50:4<652::aid-cncr2820500406>3.0.co;2-8","volume":"50","author":"J Klastersky","year":"1982","unstructured":"Klastersky J, Nicaise C, Longeval E, Stryckmans P (1982) Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma. Cancer 50(4):652\u2013658. https:\/\/doi.org\/10.1002\/1097-0142(19820815)50:4<652::aid-cncr2820500406>3.0.co;2-8","journal-title":"Cancer"},{"issue":"1","key":"1315_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00844642","volume":"9","author":"MA Andrykowski","year":"1986","unstructured":"Andrykowski MA (1986) Definitional issues in the study of anticipatory nausea in cancer chemotherapy. J\u00a0Behav Med 9(1):33\u201341. https:\/\/doi.org\/10.1007\/BF00844642","journal-title":"J Behav Med"},{"issue":"suppl1","key":"1315_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000227637","volume":"53","author":"M Martin","year":"1996","unstructured":"Martin M (1996) Oncology 53(suppl1):26\u201331","journal-title":"Oncology"},{"key":"1315_CR6","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) N\u00a0Engl J Med 374:1356\u20131367","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"1315_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26(Suppl 1):5\u20139. https:\/\/doi.org\/10.1007\/s00520-018-4131-3","journal-title":"Support Care Cancer"},{"issue":"2","key":"1315_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1046\/j.1523-5394.1999.07205.x","volume":"7","author":"C Lindley","year":"1999","unstructured":"Lindley C et al (1999) Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 7(2):59\u201365","journal-title":"Cancer Pract"},{"issue":"2","key":"1315_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11136-005-0580-5","volume":"15","author":"D Osoba","year":"2006","unstructured":"Osoba D et al (2006) Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment. Qual Life Res 15(2):273\u2013283","journal-title":"Qual Life Res"},{"issue":"4","key":"1315_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219\u2013227","journal-title":"Support Care Cancer"},{"issue":"2","key":"1315_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","volume":"10","author":"JM Salsman","year":"2012","unstructured":"Salsman JM et al (2012) Communicating about chemotherapy-induced nausea and vomiting: a\u00a0comparison of patient and provider perspectives. J\u00a0Natl Compr Canc Netw 10(2):149\u2013157","journal-title":"J Natl Compr Canc Netw"},{"key":"1315_CR12","unstructured":"NCCN, N.C.C.N., NCCN Clinical Pracitce Guidelines in Oncology: Antiemesis Version 2.2022.www.nccn.org"},{"issue":"1","key":"1315_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ (2019) ASCO, NCCN, MASCC\/ESMO: a\u00a0comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27(1):87\u201395","journal-title":"Support Care Cancer"},{"issue":"8","key":"1315_CR14","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986\u20131992","journal-title":"Ann Oncol"},{"key":"1315_CR15","unstructured":"Jordan K, Jahn F, Feyer P, Karthaus M, Kreye G, Leithold C, Oechsle K, Strasser F, W\u00f6ll E, W\u00f6rmann B Antiemese bei medikament\u00f6ser Tumortherapie. 05.2021. www.Onkopedia.com"},{"key":"1315_CR16","unstructured":"AMWF S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen.www.leitlinienprogramm-onkologie.de"},{"issue":"24","key":"1315_CR17","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH (2020) J\u00a0Clin Oncol 38(24):2782\u20132797","journal-title":"J Clin Oncol"},{"issue":"1","key":"1315_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00520-016-3384-y","volume":"25","author":"LL Dupuis","year":"2017","unstructured":"Dupuis LL, Sung L, Molassiotis A, Orsey AD, Tissing W, van de Wetering M (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25(1):323\u2013331","journal-title":"Support Care Cancer"},{"key":"1315_CR19","doi-asserted-by":"publisher","first-page":"212285","DOI":"10.7573\/dic.212285","volume":"4","author":"M Turini","year":"2015","unstructured":"Turini M et al (2015) An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context 4:212285","journal-title":"Drugs Context"},{"issue":"9","key":"1315_CR20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","volume":"16","author":"BL Rapoport","year":"2015","unstructured":"Rapoport BL et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16(9):1079\u20131089","journal-title":"Lancet Oncol"},{"issue":"9","key":"1315_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","volume":"16","author":"LS Schwartzberg","year":"2015","unstructured":"Schwartzberg LS et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a\u00a0randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 16(9):1071\u20131078","journal-title":"Lancet Oncol"},{"issue":"7","key":"1315_CR22","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro M et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a\u00a0fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25(7):1328\u20131333","journal-title":"Ann Oncol"},{"issue":"7","key":"1315_CR23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ et al (2014) A phase III study evaluating the safety and efficacy of NEPA, a\u00a0fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25(7):1333\u20131339","journal-title":"Ann Oncol"},{"issue":"7","key":"1315_CR24","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdu110","volume":"25","author":"PJ Hesketh","year":"2014","unstructured":"Hesketh PJ et al (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a\u00a0randomized dose-ranging pivotal study. Ann Oncol 25(7):1340\u20131346","journal-title":"Ann Oncol"},{"issue":"14","key":"1315_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2217\/fon-2020-0187","volume":"16","author":"M Karthaus","year":"2020","unstructured":"Karthaus M, Oskay-\u00d6zcelik G, W\u00fclfing P, Hielscher C, Guth D, Zahn MO, Flahaut E, Schilling J (2020) Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life. Future Oncol 16(14):939\u2013953","journal-title":"Future Oncol"},{"issue":"5","key":"1315_CR26","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/cam4.2091","volume":"8","author":"L Schwartzberg","year":"2019","unstructured":"Schwartzberg L, Karthaus M, Rossi G, Rizzi G, Borroni ME, Rugo HS, Jordan K, Hansen V (2019) Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. Cancer Med 8(5):2064\u20132073","journal-title":"Cancer Med"},{"issue":"1","key":"1315_CR27","first-page":"24","volume":"5","author":"MV Brafford","year":"2014","unstructured":"Brafford MV, Glode A (2014) Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J\u00a0Adv Pract Oncol 5(1):24\u201329","journal-title":"J Adv Pract Oncol"},{"key":"1315_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L et al (2009) Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J\u00a0Exp Clin Cancer Res 28:131","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"1315_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a\u00a0randomized phase III trial. J\u00a0Support Oncol 9(5):188\u2013195","journal-title":"J Support Oncol"},{"issue":"7","key":"1315_CR30","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00520-020-05935-7","volume":"29","author":"R Chow","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E, Lock M, DeAngelis C, Navari RM (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a\u00a0systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29(7):3439\u20133459","journal-title":"Support Care Cancer"},{"issue":"8","key":"1315_CR31","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/nu9080867","volume":"9","author":"W Marx","year":"2017","unstructured":"Marx W, McCarthy AL, Ried K, McKavanagh D, Vitetta L, Sali A, Lohning A, Isenring E (2017) The effect of a\u00a0standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: a double blind, randomized, placebo controlled trial. Nutrients 9(8):867","journal-title":"Nutrients"},{"issue":"11","key":"1315_CR32","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","volume":"31","author":"P Grimison","year":"2020","unstructured":"Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, Olver I, Walsh A, McGregor I, Cheung Y, Tognela A, Hahn C, Briscoe K, Aghmesheh M, Fox P, Abdi E, Clarke S, Della-Fiorentina S, Shannon J, Gedye C, Begbie S, Simes J, Stockler M (2020) Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a\u00a0randomised, placebo-controlled, phase II crossover trial. Ann Oncol 31(11):1553\u20131560","journal-title":"Ann Oncol"},{"key":"1315_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009464.pub2","author":"LA Smith","year":"2015","unstructured":"Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD009464.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1315_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JOP.2012.000816","volume":"10","author":"JW Gilmore","year":"2014","unstructured":"Gilmore JW et al (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J\u00a0Oncol Pract 10(1):68\u201374","journal-title":"J Oncol Pract"},{"issue":"1","key":"1315_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/10408398.2013.865590","volume":"57","author":"W Marx","year":"2017","unstructured":"Marx W, Ried K, McCarthy AL, Vitetta L, Sali A, McKavanagh D, Isenring L (2017) Ginger-mechanism of action in chemotherapy-induced nausea and vomiting: a review. Crit Rev Food Sci Nutr 57(1):141\u2013146","journal-title":"Crit Rev Food Sci Nutr"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-023-01315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-023-01315-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-023-01315-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T15:18:49Z","timestamp":1687879129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-023-01315-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s00106-023-01315-9","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"assertion":[{"value":"2 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M.\u00a0Karthaus<\/b>: A.\u00a0Finanzielle Interessen: Vortragshonorar: Riemser.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt Klinik f\u00fcr H\u00e4matologie und Onkologie, Klinikum Neuperlach, M\u00fcnchen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}